AzTrials
AzTrials

Overactive BladderNCT07178314

At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women

A study testing Transcutaneous Tibial Nerve Stimulation (TTNS) in people with Overactive Bladder, run by Oregon Health and Science University at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study contains a mixed-methods design consisting of a single-arm, interventional study and prospective patient interviews evaluating a novel self-implemented at-home Transcutaneous Tibial Nerve Stimulation (TTNS) treatment protocol for management of treatment naïve overactive bladder (OAB) among rural-dwelling… Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Overactive Bladder
What is being tested?
Transcutaneous Tibial Nerve Stimulation (TTNS)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
38 participants
Where
1 siteUnited States
Study dates
6 Oct 2025to Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Rural residence (as defined by the Federal Office of Rural Health policy confirmed with the "Am I rural?" tool)
  • Clinical diagnosis of overactive bladder (OAB) with urinary frequency >= 8 times per day
  • Able to complete questionnaires, urination diaries, and interview in English or Spanish
  • Have reliable access to a telephone or email for communication
  • Ambulatory and able to use the toilet independently

Who cannot join

  • Unable to consent
  • Pregnancy or planning to become pregnant during the study period
  • Previous treatment for OAB including medication, intravesical botox, and/or neuromodulation use
  • Presence of pacemaker or implantable defibrillator
  • Indwelling metal in both ankles
  • Presence of leg ulcers, open wounds, or skin conditions affecting lower legs
Show all 15Show fewer
  • Absence of sensation in the lower legs
  • Active urinary tract infection
  • Predominantly stress urinary incontinence
  • Active malignancy
  • Neurogenic bladder
  • Subjective complaint of pelvic organ prolapse outside of vaginal introitus
  • Subjective symptoms of incomplete bladder emptying
  • Epilepsy
  • Peripheral artery disease affecting both legs

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Women's Health Research Unit Department of Ob/Gyn contact

503-494-3666

whru@ohsu.edu

United States1 site, 1 recruiting
  • Oregon Health & Science University

    Portland, Oregon, 97239

    Women's Health Research Unit, 503-494-3666, whru@ohsu.edu

    Recruiting

Other trials in United States

About this study

Official title: Evaluating the Feasibility and Efficacy of At-Home Transcutaneous Tibial Nerve Stimulation (TTNS) for Overactive Bladder in Rural Women

This study contains a mixed-methods design consisting of a single-arm, interventional study and prospective patient interviews evaluating a novel self-implemented at-home Transcutaneous Tibial Nerve Stimulation (TTNS) treatment protocol for management of treatment naïve overactive bladder (OAB) among rural-dwelling women. This study will be conducted in 3 rural Oregon communities where Oregon Health \& Science University satellite campuses are located.

Read the detailed description

A total of 38 participants who meet the inclusion criteria will be recruited from clinical sites in three rural Oregon counties: 1) Klamath County, 2) Jefferson County, and 3) Coos County. Potential subjects with overactive bladder (OAB) who are being seen at healthcare clinics including primary care, obstetrics and gynecology, and pelvic floor physical therapy will be informed of this research study. Interested participants will be referred to the study coordinator via a flyer. Participants will be screened by phone and if deemed eligible and elect to participate, they will be consented over the phone/web platform. The participant has the option to sign a paper consent should they not have access to the internet. This will be mailed to them with prepaid postage for return of the signed consent. If a person does not elect to participate, the study team will offer the person information about behavioral modifications for treatment of overactive bladder and/or a referral to a local pelvic floor physical therapist. All communication and patient facing information will be offered in English or Spanish, utilizing Oregon Health \& Science University's (OHSU's) interpreter services for translation from English as described above.

Our intervention focuses on self-implemented at-home transcutaneous tibial nerve stimulation (TTNS) using a transcutaneous electrical nerve stimulation (TENS) unit. The TENS device is a nonsignificant risk device. A TENS unit with preset settings, labeled device, reusable electrodes, a battery, and detailed instructions will be mailed to the participant's designated address. All participants will receive a set of written instructions in the mail with details on skin preparation, application of the two electrodes to their ankle, connection of the electrodes to the TENS unit, standardized stimulation parameters, and adjustment of intensity to perception threshold. The written instructions will contain pictures and graphics that guide correct placement of the electrodes and use of the TENS unit settings. All participants will also be provided with a link to a short video demonstrating the application and use of the TENS unit. The script for this video is submitted with this IRB application.

Our protocol will instruct participants to use the TENS unit to deliver stimulation to the tibial nerve on one ankle for a 30-minute session, three times per week for 12 weeks starting treatment upon receipt of the device. The standardized stimulation parameters include pulse frequency of 10 Hz and pulse width of 200 ms, as used in previous studies. The intensity level is based on the participant's tolerance, ideally just above the perception threshold but not painful. Participants will be contacted by telephone at 2-3 week intervals to check on compliance with the protocol and address any issues. They will be given the study team's contact information to call sooner if questions or issues arise. Participants will also be provided with an electronic or printed 12 week calendar to keep track of completed sessions.

All participants recruited into the interventional study will also be approached and consented for possible involvement in individual interviews at their initial enrollment. Following completion of the intervention, the PI and co-investigator will use purposive sampling to identify 10-20 key informants for one-on-one video and/or audio recorded interviews with a member of the research group. Informants in the study sample are selected by investigators considering several parameters including demographic features, baseline and post-intervention scores on questionnaires from the primary and secondary outcomes previously mentioned, and compliance rate. Key informant interviews will provide insights on participant's unique experiences with self-managed TTNS at home, allowing for determination of patient perceived facilitators and barriers to this intervention. These key topics and themes can be used to inform future practices regarding self-implemented TTNS among rural dwelling patients.

A list of pre-determined, open-ended questions will be asked to each participant addressing different themes. The script and questions for the interview portion will be submitted alongside this proposal. Interviews will be recorded and transcribed verbatim using software licensed through the OHSU library (Dedoose). The software will be utilized to identify key themes emerging from the interview process. Data collection will cease once thematic saturation has been achieved, determined by the PI and co-investigator.

Being tested
Transcutaneous Tibial Nerve Stimulation (TTNS)
Keywords
Transcutaneous Tibial Nerve Stimulation (TTNS), Rural Healthcare
Medical subject headings
Urinary Bladder, Overactive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcutaneous Tibial Nerve Stimulation (TTNS)Device

    Also called TTNS, TENS Unit

    Participants will perform self-implemented at-home transcutaneous tibial nerve stimulation using a transcutaneous electrical nerve stimulation (TENS) unit. Participants will be instructed to use the TENS unit to deliver stimulation to the tibial nerve on one ankle for a 30-minute session, three times per week for 12 weeks upon receipt of the device. Intensity will be based on the participant's tolerance, just above the perception threshold but not painful.

Study groups in NCT07178314
Study groupRoleWhat they receive
Rural Women Treated with Transcutaneous Tibial Nerve StimulationExperimentalParticipants will undergo a self-implemented at-home Transcutaneous Tibial Nerve Stimulation (TTNS) treatment protocol for management of treatment naive overactive bladder (OAB) among rural dwelling women.
Receives: Device: Transcutaneous Tibial Nerve Stimulation (TTNS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overactive Bladder questionnaire short form (OAB-q SF) Health-related Quality of life

    A 13-item survey assessing health-related quality of life. Assessed on a scale from 1 to 100 with a higher score representing a better quality of life.

    Measured: Evaluated upon enrollment and following 12 weeks of intervention

  2. Overactive Bladder questionnaire short form (OAB-q SF) symptom bother

    A 13-item survey assessing symptom bother related to overactive bladder. Assessed on a scale from 1 to 100 with a higher score representing more bother, which is a worse outcome.

    Measured: Evaluated upon enrollment and following 12 weeks of intervention

  3. 24-hour voiding frequency

    Mean 24-hour voiding frequency based on a 3-day voiding diary

    Measured: 3-day voiding diary completed upon enrollment and following 12 weeks of intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2025
  2. Study start6 Oct 2025
  3. Primary completionOct 2026 (estimated)
  4. Study completionOct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
All study participants will receive the intervention.
Masking
None (open label)
Enrolment
38 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07178314
Sponsor's protocol ID
STUDY00028373
Status last verified
Oct 2025
First submitted
10 Sep 2025
Last updated
14 Oct 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Transcutaneous Tibial Nerve Stimulation (TTNS) in people with Overactive Bladder, run by Oregon Health and Science University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Women's Health Research Unit Department of Ob/Gyn (503-494-3666, whru@ohsu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overactive Bladder questionnaire short form (OAB-q SF) Health-related Quality of life (time frame: Evaluated upon enrollment and following 12 weeks of intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in